ORIC Pharmaceuticals announced promising Phase 1b data for enozertinib in first-line NSCLC patients with EGFR atypical mutations, showing an 84% systemic response rate and 70% intracranial response rate despite high baseline brain metastases. The drug demonstrated a favorable safety profile with no treatment-related discontinuations. Supported by these results and FDA interactions, ORIC plans to start a global Phase 3 trial, Redwood-1, in the first half of 2027, aiming to enroll around 360 patients. This advancement positions ORIC as a late-stage oncology company with significant commercial potential in lung and prostate cancers.
ORIC Pharmaceuticals' enozertinib shows promising Phase 1b data in NSCLC patients with EGFR atypical mutations. For readers following the Health sector, here is Pluang's market snapshot as of Oct 23, 2026 14:31 WIB: out of 150 priced Health-sector US stocks, 63 rose and 85 fell. Notable movers include GMED at USD 81.57 (+3.67%), NTRA at USD 398.34 (-3.64%), and TNGX at USD 27.91 (+3.45%) with 100% buy order activity on Pluang and a typical hold time of 2 days.
Ipsos posted €636.2 million revenue in Q3 2026 with 2.0% organic growth, up from 0.8% in H1, led by strong performances in EMEA, China, and its Citizens business. The company updated its full-year organic growth outlook to 1.2%-1.5%, citing ongoing g...
Ipsos achieved 2.0% organic revenue growth in Q3 2026, up from 0.8% in H1, driven by strong performances in EMEA, China, and citizen-related activities. The company updated its 2026 organic growth target to 1.2%-1.5%, reflecting improved momentum and...
Signify reported third-quarter 2026 results with sales of EUR 1,367 million, a slight decline in comparable sales by 3.4%, but improved adjusted EBITA of EUR 145 million and a margin increase to 10.6%. Net income rose to EUR 88 million and free cash ...
A single cryptocurrency wallet sold 246.25 BTC worth $20.64 million and purchased 8,286 ETH of equal value, indicating a rotation from Bitcoin to Ether rather than new capital entering the market. Over 11 days, the wallet sold 1,917.7 BTC for $159 mi...
Ondine Biomedical's Steriwave antimicrobial treatment reduced surgical-site infections by 51.5% at the University of Ottawa Heart Institute, Canada's largest cardiac center, dropping infection rates from 3.3% to 1.6% in 2,172 procedures. Patient comp...
